Global Gemcitabine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Gemcitabine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Gemcitabine (CAS 95058-81-4), C9H11F2N3O4, the formula weight is 263.2, and its form is white to yellow powder.
Gemcitabine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gemcitabine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
Gemcitabine is used as a second-line treatment for patients with advanced pancreatic cancer after fluorouracil failure, and can improve the quality of life of patients. Secondly, it is a first-line application for locally advanced (stage III) and already metastatic (stage IV) non-small cell lung cancer.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gemcitabine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Lilly France
Hansoh Pharma
Hisun Pharma
Pude Pharma
Qilu Pharma
Jari Pharma
HPGC
Yibantian Pharma
Actavis
Accord Healthcare
Mylan
Novartis
Salius Pharma
Segment by Type
1g/Vial
200mg/Vial
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Gemcitabine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gemcitabine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gemcitabine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Gemcitabine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gemcitabine introduction, etc. Gemcitabine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Gemcitabine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Gemcitabine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gemcitabine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
Gemcitabine is used as a second-line treatment for patients with advanced pancreatic cancer after fluorouracil failure, and can improve the quality of life of patients. Secondly, it is a first-line application for locally advanced (stage III) and already metastatic (stage IV) non-small cell lung cancer.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gemcitabine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Lilly France
Hansoh Pharma
Hisun Pharma
Pude Pharma
Qilu Pharma
Jari Pharma
HPGC
Yibantian Pharma
Actavis
Accord Healthcare
Mylan
Novartis
Salius Pharma
Segment by Type
1g/Vial
200mg/Vial
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Gemcitabine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gemcitabine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gemcitabine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Gemcitabine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gemcitabine introduction, etc. Gemcitabine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Gemcitabine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.